{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-022764","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.819575+00:00","generated_at":"2026-05-26T11:26:30.458485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates","bullets":["FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).","FY2024 net loss $76.4M ($0.63 basic EPS) vs $143.1M ($1.25) prior year; cash $109.1M (Dec 2024) vs $192.4M.","Phase 3 SENTRY myelofibrosis trial: endpoint updated to Abs-TSS; top-line data expected 2H 2025; enrollment complete 1H 2025.","Phase 3 XPORT-EC-042 endometrial cancer trial modified: focus on pMMR/dMMR ineligible for checkpoint inhibitors; sample size 276; data mid-2026.","FY2025 guidance: total revenue $140-155M; US XPOVIO net product rev $115-130M; R&D+SG&A $240-255M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-022764","json":"https://secwatch.observer/filing/0000950170-25-022764.json","markdown":"https://secwatch.observer/filing/0000950170-25-022764.md","text":"https://secwatch.observer/filing/0000950170-25-022764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/0000950170-25-022764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/kpti-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T11:26:30.458485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}